Indonesia's Attractiveness In Terms of BMI's Pharmaceutical Business Environment Ratings (BERs)

BMI View: While there are numerous factors inhibiting multinational investment in the Indonesian pharmaceuticals and healthcare market, including as a small market size compared with its Asia Pacific neighbours, corruption and a poor IP environment, BMI believes factors such as the annual growth the market, combined with rising population numbers and a relatively solid economic base, will continue to provide substantial income to companies operating in the country, encouraging multinationals to invest in the Asian

To read the full article, please choose one of the following options: